X
LinkedIn
Glassdoor
Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced three wholly owned GalNAc-AIMer preclinical programs that offer first-in-class approaches to address unmet needs in cardiometabolic diseases
WVE-007 (INHBE GalNAc-siRNA) clinical trial on track for 1Q 2025; preclinical data demonstrates opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s
Received supportive initial feedback from FDA on WVE-003; FDA is engaged in discussing pathways to accelerated approval and open to Wave’s plan to evaluate biomarkers, including caudate atrophy, as an endpoint to evaluate HD progression; IND submission expected in 2H 2025
Delivered positive interim data from FORWARD-53 study of WVE-N531; expect feedback on a pathway to accelerated approval from regulators, as well as the complete 48-week FORWARD-53 data, in 1Q 2025
Cash and cash equivalents of
Investor conference call and webcast at
“Since the start of the third quarter, we have delivered positive clinical updates across DMD and AATD, unlocked RNA editing for Wave, and advanced our novel, wholly owned pipeline focused on GalNAc-conjugated programs,” said
Recent Business Highlights
GalNAc-RNA editing
AATD
- WVE-006 is a GalNAc-conjugated, subcutaneously delivered, A-to-I RNA editing oligonucleotide (AIMer) that is uniquely designed to address Alpha-1 antitrypsin deficiency (AATD)-related lung disease, liver disease, or both. WVE-006 does not use a lipid-nanoparticle (LNP) delivery system.
- There are an estimated 200,000 Pi*ZZ patients in the US and
Europe . Treatment options are currently limited to weekly IV augmentation therapy for lung disease only (representing over$1 billion in worldwide sales in 2023). There are no approved therapies to address AATD liver disease, which ultimately requires many patients to undergo liver transplantation. - WVE-006 is currently being evaluated in the top dose cohort of RestorAATion-1 (healthy volunteers) and in the first dose cohort of RestorAATion-2 in Pi*ZZ patients with AATD.
- In October, Wave announced positive proof-of-mechanism data from the first single dose cohort with the first two patients to reach day 57 in the ongoing RestorAATion-2 study, representing the first-ever clinical demonstration of RNA editing in humans. Circulating wild-type M-AAT protein in plasma reached a mean of 6.9 micromolar at day 15, representing more than 60% of total AAT. Mean total AAT protein increased from below the level of quantification at baseline to 10.8 micromolar at day 15, meeting the level that has been the basis for regulatory approval for AAT augmentation therapies. Increases in neutrophil elastase inhibition from baseline were consistent with production of functional M-AAT. WVE-006 was well-tolerated with a favorable safety profile across both RestorAATion-1 and RestorAATion-2.
- Expected upcoming milestone: Wave expects to share multidose data from RestorAATion-2 in 2025.
New AIMers
- At Research Day in October, Wave announced three new, wholly owned RNA editing programs that build on its recent achievement of the first-ever therapeutic RNA editing with WVE-006 in AATD. As with WVE-006, these programs leverage GalNAc conjugation and have efficient clinical paths to proof-of-concept. These new programs include PNPLA3, which aims to use an mRNA correction treatment approach for those at high risk for a variety of liver diseases, and LDLR and APOB which utilize first-in-class mRNA upregulation and mRNA correction treatment approaches (respectively) to achieve target LDL-c levels in heterozygous familial hypercholesterolemia patients.
- Expected upcoming milestone: Wave expects to select clinical candidates for PNPLA3, LDLR and APOB in 2025.
Obesity (GalNAc-siRNA)
- WVE-007 is a GalNAc-conjugated small interfering RNA (GalNAc-siRNA) that targets INHBE as a novel approach to treat obesity. The approach is based on human genetics, where individuals who have a protective loss-of-function mutation in the INHBE gene have a healthier cardiometabolic profile, including less unhealthy visceral fat, lower triglycerides, and lower risk of type 2 diabetes and cardiovascular disease.
- At its recent Research Day, Wave shared data supporting WVE-007’s potential to address obesity as a monotherapy, as an add-on to GLP-1s for further improvement of weight loss or to reduce the doses of GLP-1s, and for maintenance to prevent weight regain and weight cycling after discontinuing GLP-1s.
- Expected upcoming milestone: Wave expects to initiate a clinical trial for WVE-007 in the first quarter of 2025.
HD (allele-selective silencing)
- WVE-003 is a first-in-class, allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). Results of the SELECT-HD clinical trial demonstrated the first-ever allele-selective reductions in CSF mutant huntingtin (mHTT) protein and preservation of healthy, wild-type huntingtin (wtHTT) protein with multiple doses of WVE-003, as well as a statistically significant correlation between mHTT reductions and slowing of caudate atrophy. By sparing wtHTT protein, which is critical to the health of the central nervous system, WVE-003 is uniquely positioned to address presymptomatic HD patients, as well as symptomatic patients.
- There are currently no disease modifying therapies for HD, which affects over 200,000 individuals across pre-symptomatic and symptomatic disease stages in the US and
Europe . WVE-003 is expected to address approximately 40% of the HD population (potential$5 billion commercial opportunity), and up to 80% of patients with HD may be addressed in the future with other SNP-targeted candidates (potential$10 billion commercial opportunity). - At Wave’s recent Research Day,
Jeffrey Long , PhD, Professor of Psychiatry and Biostatistics at theUniversity of Iowa , discussed the opportunity for caudate atrophy as a biomarker to expedite clinical development in HD.Dr. Long shared data which supports that the slowing of caudate atrophy predicts significant delays in the loss of function for people living with HD. The potential for changes in caudate volume to predict clinical outcomes in HD and its sensitivity to change early in the disease course makes it an optimal biomarker to enable smaller, more efficient clinical trials. - In
November 2024 , Wave received supportive initial feedback from FDA, who recognize the severity of HD and are receptive to and engaged with Wave regarding a potential pathway to accelerated approval. FDA is open to Wave’s plan to evaluate biomarkers, including caudate atrophy, as an endpoint to assess HD progression with the potential to predict clinical outcome. Planning is underway for a global, potentially registrational Phase 2/3 study of WVE-003, including finalization of key aspects of design. - In
November 2024 , the FDA granted Orphan Drug Designation to WVE-003. - Expected upcoming milestone: Wave expects to submit an Investigational New Drug (“IND”) application for WVE-003 in the second half of 2025.
DMD (exon skipping)
- WVE-N531 is an exon skipping oligonucleotide designed to induce production of endogenous, functional dystrophin protein for the treatment of boys with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. In the third quarter, the FDA granted Rare Pediatric Disease Designation and Orphan Drug Designation to WVE-N531.
- In September, Wave announced positive interim data from the Phase 2 FORWARD-53 study of WVE-N531. The interim analysis was conducted after 24 weeks of 10 mg/kg dosing every two weeks. Dystrophin results, from a pre-specified analysis of ambulatory boys, showed mean absolute muscle content-adjusted dystrophin expression was 9.0% (range: 4.6-13.9%) as measured by Western Blot. The dystrophin expression was quantified from two isoforms consistent with those observed in Becker muscular dystrophy patients who display milder disease. 89% of ambulatory participants achieved muscle content-adjusted dystrophin levels of at least 5%. Mean exon skipping was 57% (range: 31-75%) as measured by RT-PCR.
- WVE-N531 could address up to 10% of the DMD population, which encompasses over 2,000 boys in the US and
Europe . Wave is also advancing a broader DMD pipeline of oligonucleotides for skipping other exons, with the goal of providing new and best-in-class treatment options for up to 40% of boys with DMD. In 2023, exon skipping therapeutics for DMD achieved approximately~$1 billion in sales, primarily in the US, across exons covering approximately ~29% of the DMD population. - Expected upcoming milestone: In the first quarter of 2025, Wave expects to deliver the complete 48-week FORWARD-53 data and receive feedback from regulators on a pathway to accelerated approval.
Financial Highlights
- Cash and cash equivalents were
$310.9 million as ofSeptember 30, 2024 , as compared to$200.4 million as ofDecember 31, 2023 . In the third quarter of 2024, Wave received approximately$187.5 million in net proceeds from the upsizedSeptember 2024 offering. Subsequent to the third quarter of 2024, onOctober 1, 2024 , Wave received approximately$28.2 million in net proceeds from theSeptember 2024 offering. Wave expects that its current cash and cash equivalents will be sufficient to fund operations into 2027. Potential future milestone and other payments to Wave under its GSK collaboration are not included in its cash runway. - Revenue recognized was
($7.7) million for the third quarter of 2024, as compared to$49.2 million in the third quarter of 2023, which included one-time revenue recognition events under our Takeda Collaboration related to the termination of the C9 program and the achievement of a development milestone. The year over year decrease is primarily driven by these one-time events in the prior year period. In addition, under our GSK collaboration, we recorded a non-cash reduction to cumulative revenue in the current period due to a change in the estimate to fulfill the performance obligations in accordance with revenue recognition standards. This adjustment changes the timing of revenue reporting for this program, with no impact on the program’s progress or cash flow. - Research and development expenses were
$41.2 million in the third quarter of 2024, as compared to$31.6 million in the third quarter of 2023. General and administrative expenses were$15.0 million in the third quarter of 2024, as compared to$13.1 million in the third quarter of 2023. - Net loss was
$61.8 million for the third quarter of 2024, as compared to net income of$7.3 million for the third quarter of 2023.
Investor Conference Call and Webcast
Wave will host an investor conference call today at
About Wave Life Sciences
Forward-Looking Statements
This press release contains forward-looking statements concerning our goals, beliefs, expectations, strategies, objectives and plans, and other statements that are not necessarily based on historical facts, including statements regarding the following, among others: the anticipated initiation, site activation, patient recruitment, patient enrollment, dosing, generation and reporting of data and completion of our clinical trials, including interactions with regulators and any potential registration based on these data, and the timing and announcement of such events; the protocol, design and endpoints of our clinical trials; the future performance and results of our programs in clinical trials; our expectations with respect to how our clinical data successes to date may predict success for our future therapeutic candidates, future clinical data readouts and further validate of our platform; ongoing and future preclinical activities and programs, and their potential to transition into clinical-stage programs ; the potential of our preclinical data to predict the behavior of our compounds in humans; regulatory submissions and timing for regulatory feedback; the progress and potential benefits of our collaborations; the potential achievement of milestones under our collaborations and receipt of cash payments therefor; the potential commercial opportunities that our therapeutic candidates may address; our identification and expected timing of future product candidates and their therapeutic potential; the anticipated benefits of our therapeutic candidates and pipeline compared to our competitors; patient population estimates related to our therapeutic candidates; our ability to design compounds using various modalities and the anticipated benefits of that approach; the breadth and versatility of our PRISM drug discovery and development platform; the expected benefits of our stereopure oligonucleotides compared with stereorandom oligonucleotides; the potential benefits of our RNA editing capability, including our AIMers, compared to others; the potential for certain of our programs to be best-in-class or first-in-class; the potential benefits that our “edit-verse” may provide us, including identifying new RNA editing targets; the status and progress of our programs relative to potential competitors; anticipated benefits of our proprietary manufacturing processes and our internal manufacturing capabilities; the benefits of RNA medicines generally; the strength of our intellectual property and the data that support our IP; the anticipated duration of our cash runway and our ability to fund future operations; our intended uses of capital; and our expectations regarding the impact of any potential global macro events on our business. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including the following: our ability to finance our drug discovery and development efforts and to raise additional capital when needed; the ability of our preclinical programs to produce data sufficient to support our clinical trial applications and the timing thereof; the clinical results of our programs and the timing thereof, which may not support further development of our product candidates; actions of regulatory authorities and their receptiveness to our adaptive trial designs and accelerated approval pathways, which may affect the initiation, timing and progress of clinical trials; our effectiveness in managing regulatory interactions and future clinical trials; the effectiveness of PRISM; the effectiveness of our RNA editing capability and our AIMers; our ability to demonstrate the therapeutic benefits of our candidates in clinical trials, including our ability to develop candidates across multiple therapeutic modalities; our dependence on third parties, including contract research organizations, contract manufacturing organizations, collaborators and partners; our ability to manufacture or contract with third parties to manufacture drug material to support our programs and growth; our ability to obtain, maintain and protect our intellectual property; our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; competition from others developing therapies for the indications we are pursuing; our ability to maintain the company infrastructure and personnel needed to achieve our goals; and the information under the caption “Risk Factors” contained in our most recent Annual Report on Form 10-K filed with the
UNAUDITED CONSOLIDATED BALANCE SHEETS (In thousands, except share amounts) |
||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 310,948 | $ | 200,351 | ||||
| Accounts receivable | — | 21,086 | ||||||
| Prepaid expenses | 10,572 | 9,912 | ||||||
| Other current assets | 2,995 | 4,024 | ||||||
| Total current assets | 324,515 | 235,373 | ||||||
| Long-term assets: | ||||||||
| Property and equipment, net of accumulated depreciation of as of |
10,928 | 13,084 | ||||||
| Operating lease right-of-use assets | 19,119 | 22,637 | ||||||
| Restricted cash | 3,746 | 3,699 | ||||||
| Other assets | 196 | 156 | ||||||
| Total long-term assets | 33,989 | 39,576 | ||||||
| Total assets | $ | 358,504 | $ | 274,949 | ||||
| Liabilities, Series A preferred shares, and shareholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 12,781 | $ | 12,839 | ||||
| Accrued expenses and other current liabilities | 14,642 | 16,828 | ||||||
| Current portion of deferred revenue | 135,907 | 150,059 | ||||||
| Current portion of operating lease liability | 7,398 | 6,714 | ||||||
| Total current liabilities | 170,728 | 186,440 | ||||||
| Long-term liabilities: | ||||||||
| Deferred revenue, net of current portion | 18,490 | 15,601 | ||||||
| Operating lease liability, net of current portion | 19,772 | 25,404 | ||||||
| Total long-term liabilities | 38,262 | 41,005 | ||||||
| Total liabilities | $ | 208,990 | $ | 227,445 | ||||
| Series A preferred shares, no par value; 3,901,348 shares issued and outstanding at |
$ | 7,874 | $ | 7,874 | ||||
| Shareholders’ equity: | ||||||||
| Ordinary shares, no par value; 148,392,939 and 119,162,234 shares issued and outstanding at |
$ | 1,139,714 | $ | 935,367 | ||||
| Additional paid-in capital | 153,196 | 129,237 | ||||||
| Accumulated other comprehensive loss | (159 | ) | (124 | ) | ||||
| Accumulated deficit | (1,151,111 | ) | (1,024,850 | ) | ||||
| Total shareholders’ equity | $ | 141,640 | $ | 39,630 | ||||
| Total liabilities, Series A preferred shares, and shareholders’ equity | $ | 358,504 | $ | 274,949 | ||||
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (In thousands, except share and per share amounts) |
||||||||||||||||
| Three Months Ended |
Nine Months Ended |
|||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenue | $ | (7,676 | ) | $ | 49,214 | $ | 24,554 | $ | 84,249 | |||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 41,197 | 31,642 | 115,037 | 95,935 | ||||||||||||
| General and administrative | 15,042 | 13,128 | 42,887 | 37,628 | ||||||||||||
| Total operating expenses | 56,239 | 44,770 | 157,924 | 133,563 | ||||||||||||
| Income (loss) from operations | (63,915 | ) | 4,444 | (133,370 | ) | (49,314 | ) | |||||||||
| Other income, net: | ||||||||||||||||
| Dividend income and interest income | 1,798 | 1,960 | 6,425 | 6,084 | ||||||||||||
| Other income, net | 337 | 171 | 684 | 1,296 | ||||||||||||
| Total other income, net | 2,135 | 2,131 | 7,109 | 7,380 | ||||||||||||
| Income (loss) before income taxes | (61,780 | ) | 6,575 | (126,261 | ) | (41,934 | ) | |||||||||
| Income tax benefit (provision) | — | 677 | — | 677 | ||||||||||||
| Net income (loss) | $ | (61,780 | ) | $ | 7,252 | $ | (126,261 | ) | $ | (41,257 | ) | |||||
| Less: net income attributable to participating securities |
$ | — | $ | (257 | ) | $ | — | $ | — | |||||||
| Net income (loss) attributable to ordinary shareholders, basic and diluted |
$ | (61,780 | ) | $ | 6,995 | $ | (126,261 | ) | $ | (41,257 | ) | |||||
| Net income (loss) per share attributable to ordinary shareholders—basic |
$ | (0.47 | ) | $ | 0.07 | $ | (0.97 | ) | $ | (0.39 | ) | |||||
| Weighted-average ordinary shares used in computing net income (loss) per share attributable to ordinary shareholders—basic |
132,563,467 | 106,025,063 | 130,470,603 | 104,529,266 | ||||||||||||
| Net income (loss) per share attributable to ordinary shareholders—diluted |
$ | (0.47 | ) | $ | 0.07 | $ | (0.97 | ) | $ | (0.39 | ) | |||||
| Weighted-average ordinary shares used in computing net income (loss) per share attributable to ordinary shareholders—diluted |
132,563,467 | 106,975,231 | 130,470,603 | 104,529,266 | ||||||||||||
| Other comprehensive income (loss): | ||||||||||||||||
| Net income (loss) | $ | (61,780 | ) | $ | 7,252 | $ | (126,261 | ) | $ | (41,257 | ) | |||||
| Foreign currency translation | 120 | (32 | ) | (35 | ) | (153 | ) | |||||||||
| Comprehensive income (loss) | $ | (61,660 | ) | $ | 7,220 | $ | (126,296 | ) | $ | (41,410 | ) | |||||
Investor Contact:
+1 617-949-4827
krausch@wavelifesci.com
Media Contact:
+1 617-949-4817
asuter@wavelifesci.com
Source: Wave Life Sciences USA, Inc.